STOCK TITAN

Moderna Named a Top Employer by Science for Tenth Consecutive Year

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Very Positive)
Tags

Moderna (NASDAQ:MRNA) has been named a top employer in the global biopharmaceutical industry by Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. The company was recognized for its innovation, employee respect, and social responsibility.

Key 2024 achievements include implementing ChatGPT Enterprise across the organization, establishing a new global headquarters in Cambridge, Massachusetts, and continuing development of a Marlborough manufacturing site. The company also celebrated the second anniversary of its Charitable Foundation and released its third ESG Report.

The Science survey gathered over 6,400 responses from readers worldwide, with 65% from North America, 19% from Europe, and 11% from Asia/Pacific Rim.

Moderna (NASDAQ:MRNA) è stata nominata miglior datore di lavoro nell'industria biopharmaceutica globale dal Science e dal Science Careers nel loro sondaggio sui migliori datori di lavoro del 2024 per il decimo anno consecutivo. L'azienda è stata riconosciuta per la sua innovazione, il rispetto per i dipendenti e la responsabilità sociale.

Tra i risultati chiave del 2024 ci sono l'implementazione del ChatGPT Enterprise in tutta l'organizzazione, l'istituzione di un nuovo quartier generale globale a Cambridge, Massachusetts, e il continuo sviluppo di un sito di produzione a Marlborough. L'azienda ha anche celebrato il secondo anniversario della sua Fondazione Charitable e ha pubblicato il suo terzo Rapporto ESG.

Il sondaggio di Science ha raccolto oltre 6,400 risposte da lettori di tutto il mondo, con il 65% provenienti dal Nord America, il 19% dall'Europa e l'11% dall'Asia/Pacifico.

Moderna (NASDAQ:MRNA) ha sido nombrada como uno de los mejores empleadores en la industria biofarmacéutica global en la encuesta de Science y Science Careers sobre los mejores empleadores de 2024, por décimo año consecutivo. La compañía fue reconocida por su innovación, el respeto hacia los empleados y su responsabilidad social.

Los logros clave de 2024 incluyen la implementación de ChatGPT Enterprise en toda la organización, el establecimiento de una nueva sede central global en Cambridge, Massachusetts, y la continuación del desarrollo de un sitio de fabricación en Marlborough. La compañía también celebró el segundo aniversario de su Fundación Caritativa y lanzó su tercer Informe ESG.

La encuesta de Science reunió más de 6,400 respuestas de lectores de todo el mundo, con un 65% de América del Norte, un 19% de Europa y un 11% de Asia/Pacífico.

모더나(NASDAQ:MRNA)ScienceScience Careers의 2024년 최고의 고용주 조사에서 10년 연속 글로벌 생명공학 산업 최고의 고용주로 선정되었습니다. 이 회사는 혁신, 직원 존중 및 사회적 책임에 대해 인정받았습니다.

2024년의 주요 성과로는 조직 전반에 걸쳐 ChatGPT Enterprise를 구현하고, 매사추세츠주 캠브리지에 새로운 글로벌 본사를 설립하며, 말보로 제조 사이트의 개발을 계속하는 것이 포함됩니다. 이 회사는 또한 자선 재단의 2주년을 축하하고 세 번째 ESG 보고서를 발표했습니다.

Science의 조사에서는 전 세계 독자로부터 6,400회 이상의 응답을 수집했으며, 북미에서 65%, 유럽에서 19%, 아시아/태평양 지역에서 11%의 응답이 있었습니다.

Moderna (NASDAQ:MRNA) a été nommé meilleur employeur dans l'industrie biopharmaceutique mondiale par Science et Science Careers dans leur enquête sur les meilleurs employeurs de 2024, pour la dixième année consécutive. L'entreprise a été reconnue pour son innovation, le respect de ses employés et sa responsabilité sociale.

Les réalisations clés de 2024 comprennent la mise en œuvre de ChatGPT Enterprise dans toute l'organisation, l'établissement d'un nouveau siège social mondial à Cambridge, Massachusetts, et le développement continu d'un site de fabrication à Marlborough. L'entreprise a également célébré le deuxième anniversaire de sa Fondation Caritative et a publié son troisième Rapport ESG.

L'enquête de Science a recueilli plus de 6 400 réponses de lecteurs du monde entier, 65 % provenant d'Amérique du Nord, 19 % d'Europe et 11 % d'Asie/Pacifique.

Moderna (NASDAQ:MRNA) wurde bei der Science und Science Careers 2024 Umfrage zu den besten Arbeitgebern für die zehnte aufeinanderfolgende Jahr als bester Arbeitgeber in der globalen biopharmazeutischen Industrie ausgezeichnet. Das Unternehmen wurde für seine Innovation, den respektvollen Umgang mit Mitarbeitern und soziale Verantwortung anerkannt.

Wichtige Erfolge im Jahr 2024 umfassen die Implementierung von ChatGPT Enterprise im gesamten Unternehmen, die Einrichtung eines neuen globalen Hauptsitzes in Cambridge, Massachusetts, und die fortlaufende Entwicklung eines Produktionsstandorts in Marlborough. Das Unternehmen feierte zudem das zwei Jahre Bestehen seiner Stiftung und veröffentlichte seinen dritten ESG-Bericht.

Die Umfrage von Science sammelte über 6.400 Antworten von Lesern weltweit, wobei 65 % aus Nordamerika, 19 % aus Europa und 11 % aus Asien/Pazifik stammten.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.

"We are honored to be recognized among the top employers in the industry for 10 years in a row," said Stéphane Bancel, Chief Executive Officer of Moderna. "This milestone underscores our dedication to fostering a digital-first, inclusive environment where our team can innovate and drive meaningful advancements to mRNA science and human health."

In 2024, Moderna invested in a strategic collaboration with OpenAI to deploy ChatGPT Enterprise across the organization, empowering every function to create novel use cases and GPTs to streamline workflows and achieve operational efficiency. Moderna also brought together its Cambridge, Massachusetts-based workforce in a new global headquarters, and continued a build-out of a manufacturing site in Marlborough, Massachusetts, to enable future manufacturing. As part of Moderna's ongoing commitment to social responsibility, the Company also marked the second anniversary of the Moderna Charitable Foundation and issued its third annual ESG Report.

"At Moderna, we are motivated by our potential to change the future of medicine," said Tracey Franklin, Chief Human Resources Officer of Moderna. "The Company has grown substantially since the first time we were included on Science's Top Employers list, but our team's commitment to excellence has never wavered. We remain dedicated to cultivating a workplace where curiosity and purpose thrive together."

For more than 20 years, Science has surveyed its readership to identify and celebrate the top 20 pharmaceutical and biotechnology companies with the best reputation as employers. The 2024 survey's findings were based on more than 6,400 completed surveys from readers of Science and other survey invitees, with responses from North America (65%), Europe (19%), and Asia/Pacific Rim (11%) and other locations (5%). A vast majority (95%) of the respondents worked in biotechnology, biopharmaceutical and pharmaceutical companies.

For the complete feature along with individual company rankings, please visit: https://www.science.org/content/article/top-20-2024-who-did-science-readers-select-best-biopharma.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Moderna Contacts

Media:
Chris Ridley
Head, Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.



View the original press release on accesswire.com

FAQ

How many consecutive years has Moderna (MRNA) been named a top employer by Science?

Moderna has been named a top employer by Science for ten consecutive years, as announced in the 2024 Top Employers Survey.

What major technological implementation did Moderna (MRNA) make in 2024?

In 2024, Moderna implemented ChatGPT Enterprise across its organization through a strategic collaboration with OpenAI to streamline workflows and achieve operational efficiency.

What new facilities did Moderna (MRNA) develop in Massachusetts in 2024?

Moderna established a new global headquarters in Cambridge, Massachusetts, and continued developing a manufacturing site in Marlborough, Massachusetts.

How many responses did Science's 2024 Top Employers Survey receive?

The 2024 Science Top Employers Survey received more than 6,400 completed surveys from readers and invitees globally.

Moderna, Inc.

NASDAQ:MRNA

MRNA Rankings

MRNA Latest News

MRNA Stock Data

21.09B
384.40M
9.52%
72.09%
8.65%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE